Adamas Pharmaceuticals Inc
ADMS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ADMS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Sep 30, 2021.
Tracking 5 pipeline candidates · 5 clinical trials for Adamas Pharmaceuticals Inc.
Run Adamas Pharmaceuticals Inc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Adamas Pharmaceuticals Inc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
43.4 months
OCF -$6M · Net income -$20M
Lead: Approved
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Frequently asked questions
What is Adamas Pharmaceuticals Inc's lead drug candidate?
Adamas Pharmaceuticals Inc's most advanced tracked candidate is ads-4101 (Preclinical) for partial onset seizures in patients with epilepsy.
Who is the CEO of Adamas Pharmaceuticals Inc?
Neil F. Mc is the chief executive officer of Adamas Pharmaceuticals Inc (ADMS).
What therapeutic areas does Adamas Pharmaceuticals Inc focus on?
Adamas Pharmaceuticals Inc develops therapies across Oncology, Neurology, Immunology, Dermatology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.